Novo Nordisk slashed its spending on TV ads for Wegovy by almost 24% between April and May, from $31.6 million to $24.1 ...

The payments have raised concerns that doctors could be influenced to favour specific drugs or prescribe them over talking ...

As has been the case for drug development for PTSD in general, Rexulti’s path so far has had its ups and downs, with the pivotal Phase III results seeing the fixed dose miss its primary endpoint ...

Rexulti has approval from the Food and Drug Administration (FDA) to treat the following conditions: It’s important to note that not treating your diagnosed condition during pregnancy may carry ...

Notable drugs facing generic competition in 2025 include ... Other branded medicines with new indications pending include brexpiprazole (Rexulti) for posttraumatic stress disorder, roflumilast ...

Rexulti (brexpiprazole) is a prescription drug that works to treat depression, schizophrenia, and other mental health conditions by changing certain brain chemicals that regulate mood. Your ...

Adverse drug reactions of acetylcholinesterase inhibitors in older ... DailyMed. Belsomra label. DailyMed. Rexulti label. Lee D, Clark ED, Antonsdottir IM, Porsteinsson AP. Brexpiprazole for agitation ...

Drug interactions associated with posaconazole ... Among them are the following: Brexpiprazole (Rexulti), an anti-psychotic with an increased half-life in people with obesity, resulting in ...

Since then, the company has launched several high-margin, differentiated drugs, including Abilify Maintena (a long-acting injectable for psychosis), Trintellix/Brintellix (depression), Rexulti ...

We forecast Vyepti and Rexulti will be the strongest growth drivers over the next few years, and these drugs will help offset generic erosion of the company’s legacy brands and approaching ...

Alembic has received permission from the Food and Drug Administration for brexpiprazole tablets, which is the generic of Otsuka’s Rexulti. Brexpiprazole is an atypical antipsychotic used as an ...

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, of Otsuka Pharmaceutical Company, Ltd.